Remove 2021 Remove Licensing Remove Treatment
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Published July 9, 2025 Gwendolyn Wu Senior reporter post share post print email license Actinium is one of several radioisotopes favored by biotechnology companies developing drugs for cancer. M Ventures, which helped found the company in 2021, co-led the Series A round with Hadean Ventures, Sofinnova Partners and 4BIO Capital.

Drugs 156
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development faces significant challenges: long timelines, high costs , complex processes and low probabilities of success (PoS), exacerbated by the shift towards more complex molecules, biologics and cell and gene therapies, hindering patient access to vital treatments. Nature, 596, 590-596 (2021) [link] Liu R, Rizzo S, Waliany S, et al.

Drugs 64
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inavolisib

New Drug Approvals

8] Therefore, it may serve as a new addition to combination therapy with conventional cancer treatment, such as chemotherapy. Combining inavolisib with palbociclib and fulvestrant might improve treatment of breast cancer. [14] Vanhaesebroeck B, Perry MW, Brown JR, Andr F, Okkenhaug K (October 2021). 22 June 2021.

FDA 57
article thumbnail

Zilucoplan

New Drug Approvals

Its sodium salt is used for the treatment of generalised myasthenia gravis (a disease that leads to muscle weakness and tiredness) in adults whose immune system produces antibodies against acetylcholine receptors. Retrieved 24 June 2021. 6] [9] [10] It is a complement inhibitor that is injected subcutaneously (under the skin). [6]

FDA 57
article thumbnail

Taletrectinib

New Drug Approvals

Medical uses Taletrectinib is indicated for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. [1] Medical uses Taletrectinib is indicated for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. [1] World Health Organization (2021).

article thumbnail

Pirtobrutinib

New Drug Approvals

1] [11] In December 2023, the US Food and Drug Administration (FDA) expanded the indication for pirtobrutinib to include the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia. [7] 7] [12] In the European Union, pirtobrutinib is indicated for the treatment of mantle cell lymphoma. [2] 27 January 2023.

article thumbnail

Crinecerfont

New Drug Approvals

Formula C 27 H 29 Cl 2 FN 2 OS Crinecerfont , sold under the brand name Crenessity , is a medication used for the treatment of congenital adrenal hyperplasia. [1] Jump up to: a b c d e f g h i j k l m n o p q “FDA Approves New Treatment for Congenital Adrenal Hyperplasia” U.S. 321839-75-2 Molecular Weight 519.50

FDA 62